HC Wainwright Weighs in on Evolus’ Q4 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS) – Stock analysts at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for Evolus in a report released on Tuesday, February 3rd. HC Wainwright analyst D. Tsao now expects that the company will earn $0.01 per share for the quarter, down from their previous estimate of $0.02. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share.

A number of other analysts have also recently issued reports on EOLS. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Mizuho set a $15.00 price target on Evolus in a research note on Wednesday. BTIG Research dropped their price objective on Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Finally, Stifel Nicolaus lowered their target price on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Evolus Stock Down 2.3%

EOLS opened at $4.59 on Wednesday. Evolus has a 12 month low of $4.48 and a 12 month high of $17.12. The company has a fifty day simple moving average of $6.11 and a 200 day simple moving average of $6.75. The stock has a market cap of $297.52 million, a P/E ratio of -4.99 and a beta of 1.11.

Evolus (NASDAQ:EOLS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million for the quarter, compared to analyst estimates of $91.23 million.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Manchester Capital Management LLC bought a new stake in shares of Evolus during the 2nd quarter valued at $26,000. State of Alaska Department of Revenue bought a new stake in Evolus during the third quarter worth about $26,000. Wexford Capital LP acquired a new stake in Evolus during the third quarter worth about $37,000. Aquatic Capital Management LLC bought a new position in Evolus in the 3rd quarter valued at about $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Evolus in the 3rd quarter valued at about $62,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider directly owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by insiders.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.